<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Alnylam18Dec-shutterstock_2714580617-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Alnylam18Dec-shutterstock_2714580617-430x241.jpg"/></p>
<p>设施扩建被认为能够支持 Alnylam 开发管线未来药物的推出。图片来源：Bo Shen / Shutterstock.com。</p>
<p>Alnylam 制药公司计划在美国马萨诸塞州诺顿市投资 2.5 亿美元，以满足全球对 RNA 干扰（RNAi）治疗药物日益增长的需求。</p>
<p>这将成为首个完全专用的小干扰 RNA（siRNA）酶连接制造设施。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: ALLO-501</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: ALLO-501A</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>设施扩建旨在提高产能，降低生产成本，并支持公司开发管线未来药物的推出。</p>
<p>作为此计划的一部分，公司下一代可扩展的酶连接制造平台 siRELIS 已被纳入美国食品药品监督管理局的前沿技术计划。</p>
<p>该计划预计将促进与全球卫生当局就基于寡核苷酸药物的制造方法进行讨论。</p>
<p>这一接受是在对 zilebesiran 进行小规模生产后，该药物正在研究降低高血压患者重大不良心血管事件的风险，以及 nucresiran，正在开发用于转甲状腺素介导的淀粉样变性（ATTR）。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>siRELIS 平台使 RNAi 治疗药物的制造所需的材料和工厂资源减少，支持可持续的大规模生产。</p>
<p>公司 20 万平方英尺的诺顿设施扩建允许在当地生产临床和商业供应的 siRNA 寡核苷酸药物原料，服务全球患者。</p>
<p>该设施自 2021 年开始运营，已为 Alnylam 的临床管线增长做出贡献，并支持针对多种组织类型的早期项目，包括中枢神经系统（CNS）、肝脏、肌肉和脂肪组织。</p>
<p>该地点的建设目前正在进行中，预计新设施将在 2027 年底前全面投入运营。</p>
<p>Alnylam 制药公司首席执行官 Yvonne Greenstreet 表示：“在我们 RNAi 治疗药物管线扩展的关键时刻，Alnylam 正在加速 siRNA 制造的发展，并改变单一设施的可能性。</p>
<p>“这一进展将是我们管线扩展的关键推动力，包括潜在治疗高血压、2 型糖尿病和肥胖等疾病。”</p>
<p>2025 年 6 月，欧洲委员会批准了 Alnylam 的 Amvuttra（vutrisiran），用于治疗成人的野生型或遗传性转甲状腺素淀粉样变性伴心肌病。</p>
<h2>制药技术卓越奖 - 提名已关闭</h2>
<p>提名现已关闭，感谢所有参与的组织——你们的响应非常出色，展示了卓越的创新、领导力和影响力。</p>
<p><strong>行动中的卓越</strong></p>
<p>Upperton Pharma Solutions 因在 综合制造 方面的业务扩展获得 2025 年制药技术卓越奖，正在迅速扩展其在英国的 GMP 和无菌制造能力。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发转向临床和小众商业供应，减少交接和加快时间表。</p>
<p>发现影响</p>

阿里拉姆制药

<p>阿里拉姆制药计划在其诺顿制造设施投资 2.5 亿美元，以增强其 siRELIS 平台用于 RNA 干扰治疗。美国食品药品监督管理局的前沿技术计划已接受该平台，促进了关于寡核苷酸药物制造的讨论。此次扩展支持可持续的大规模生产和 siRNA 药物物质的本地供应。该设施自 2021 年投入运营，助力阿里拉姆的临床管线增长，针对多种组织。预计到 2027 年底将达到全面运营能力，从而能够治疗高血压、2 型糖尿病和肥胖症</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Alnylam18Dec-shutterstock_2714580617-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Alnylam18Dec-shutterstock_2714580617-430x241.jpg"/></p>
<p>The facility expansion is said to enable support for future medicine launches from Alnylam’s development pipeline. Credit: Bo Shen / Shutterstock.com.</p>
<div class="lb-trans"><p>设施扩建被认为能够支持 Alnylam 开发管线未来药物的推出。图片来源：Bo Shen / Shutterstock.com。</p>
</div><p>Alnylam Pharmaceuticals is set to invest $250m in the expansion of its facility in Norton, Massachusetts, US, to meet the growing global demand for RNA interference (RNAi) therapeutics.</p>
<div class="lb-trans"><p>Alnylam 制药公司计划在美国马萨诸塞州诺顿市投资 2.5 亿美元，以满足全球对 RNA 干扰（RNAi）治疗药物日益增长的需求。</p>
</div><p>This is claimed to become the first fully dedicated small-interfering RNA (siRNA) enzymatic-ligation manufacturing facility.</p>
<div class="lb-trans"><p>这将成为首个完全专用的小干扰 RNA（siRNA）酶连接制造设施。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: ALLO-501</h4>
<div class="lb-trans"><h4>NPVM: ALLO-501</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: ALLO-501A</h4>
<div class="lb-trans"><h4>NPVM: ALLO-501A</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>The facility expansion is intended to increase capacity, lower production expenses, and enable support for future medicine launches from the company’s development pipeline.</p>
<div class="lb-trans"><p>设施扩建旨在提高产能，降低生产成本，并支持公司开发管线未来药物的推出。</p>
</div><p>As part of this, the company’s next-generation, scalable enzymatic ligation manufacturing platform, known as siRELIS, has been accepted into the US Food and Drug Administration’s Emerging Technology Program.</p>
<div class="lb-trans"><p>作为此计划的一部分，公司下一代可扩展的酶连接制造平台 siRELIS 已被纳入美国食品药品监督管理局的前沿技术计划。</p>
</div><p>The programme is expected to facilitate discussions with global health authorities regarding manufacturing approaches for oligonucleotide-based medicines.</p>
<div class="lb-trans"><p>该计划预计将促进与全球卫生当局就基于寡核苷酸药物的制造方法进行讨论。</p>
</div><p>This acceptance comes after pilot-scale production of zilebesiran, which is under investigation for decreasing the risk of major adverse cardiovascular events in hypertension patients, and nucresiran, being developed for transthyretin-mediated amyloidosis (ATTR).</p>
<div class="lb-trans"><p>这一接受是在对 zilebesiran 进行小规模生产后，该药物正在研究降低高血压患者重大不良心血管事件的风险，以及 nucresiran，正在开发用于转甲状腺素介导的淀粉样变性（ATTR）。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>The siRELIS platform enables RNAi therapeutic manufacturing with reduced material and plant resource requirements, supporting sustainable, large-scale production.</p>
<div class="lb-trans"><p>siRELIS 平台使 RNAi 治疗药物的制造所需的材料和工厂资源减少，支持可持续的大规模生产。</p>
</div><p>The company’s 200,000ft² Norton facility expansion allows for local production of both clinical and commercial supplies of siRNA oligonucleotide drug substance for patients worldwide.</p>
<div class="lb-trans"><p>公司 20 万平方英尺的诺顿设施扩建允许在当地生产临床和商业供应的 siRNA 寡核苷酸药物原料，服务全球患者。</p>
</div><p>Operational since 2021, the facility has contributed to the growth of Alnylam’s clinical pipeline and supports early-stage programmes targeting various tissue types, including the central nervous system (CNS), liver, muscle, and adipose tissue.</p>
<div class="lb-trans"><p>该设施自 2021 年开始运营，已为 Alnylam 的临床管线增长做出贡献，并支持针对多种组织类型的早期项目，包括中枢神经系统（CNS）、肝脏、肌肉和脂肪组织。</p>
</div><p>Construction at the site is currently underway, with the new offerings anticipated to be completely operational by late 2027.</p>
<div class="lb-trans"><p>该地点的建设目前正在进行中，预计新设施将在 2027 年底前全面投入运营。</p>
</div><p>Alnylam Pharmaceuticals CEO Yvonne Greenstreet said: “At this pivotal time with our expanding pipeline of RNAi therapeutics, Alnylam is accelerating development of siRNA manufacturing and changing what’s possible in a single facility.</p>
<div class="lb-trans"><p>Alnylam 制药公司首席执行官 Yvonne Greenstreet 表示：“在我们 RNAi 治疗药物管线扩展的关键时刻，Alnylam 正在加速 siRNA 制造的发展，并改变单一设施的可能性。</p>
</div><p>“This advance will be a critical enabler in the scaling of our pipeline to include potential treatments for diseases such as hypertension, type 2 diabetes, and obesity.”</p>
<div class="lb-trans"><p>“这一进展将是我们管线扩展的关键推动力，包括潜在治疗高血压、2 型糖尿病和肥胖等疾病。”</p>
</div><p>In June 2025, the European Commission approved Alnylam’s Amvuttra (vutrisiran) for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.</p>
<div class="lb-trans"><p>2025 年 6 月，欧洲委员会批准了 Alnylam 的 Amvuttra（vutrisiran），用于治疗成人的野生型或遗传性转甲状腺素淀粉样变性伴心肌病。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 提名已关闭</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>提名现已关闭，感谢所有参与的组织——你们的响应非常出色，展示了卓越的创新、领导力和影响力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行动中的卓越</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>Upperton Pharma Solutions 因在 综合制造 方面的业务扩展获得 2025 年制药技术卓越奖，正在迅速扩展其在英国的 GMP 和无菌制造能力。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发转向临床和小众商业供应，减少交接和加快时间表。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>发现影响</p>
</div>

阿里拉姆制药计划在美国诺顿的制造设施投资 2.5 亿美元